Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02871778 · ClinicalTrials.gov registry record · Phase 2
Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
A Phase 2 study, sponsored by Parion Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT02871778 is a Phase 2 study that has completed, run by Parion Sciences. The registered enrollment target is 123 participants.
The verdict
NCT02871778, a Phase 2 study, has completed, sponsored by Parion Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).
Interventions
- DRUG Ivacaftor
- DRUG Hypertonic Saline
- DRUG VX-371 + HS
- DRUG VX-371
- DRUG Placebo (0.17% saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2016-08 |
| Est. Completion | 2018-11-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02871778
The ClinicalTrials.gov registry entry for NCT02871778 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Parion Sciences, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ivacaftor is the first listed.
NCT02871778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02871778 about?
NCT02871778 is a clinical study titled "Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia". To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).
What is the current status of trial NCT02871778?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2016-08. Estimated completion is 2018-11-20.
What interventions are being tested in trial NCT02871778?
The interventions under investigation include: Ivacaftor (DRUG), Hypertonic Saline (DRUG), VX-371 + HS (DRUG), VX-371 (DRUG), Placebo (0.17% saline) (DRUG).
Who is sponsoring clinical trial NCT02871778?
This trial is sponsored by Parion Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.